Ceregene Advances Phase 2b CERE-120 (AAV2-neurturin) Trial in Parkinson's Disease

SAN DIEGO, Feb. 3, 2011 /PRNewswire

" To date, approximately 20 percent of the 52 subjects have undergone either CERE-120 administration or sham surgery, with many others enrolled and awaiting surgery. It is anticipated that enrollment will be completed near the end of June 2011."

" 'It is encouraging that CERE-120 continues to appear safe and that the new dosing paradigm we implemented seems well-tolerated,' stated Joao Siffert, M.D., Ceregene's vice president, chief medical officer."